Cargando…

Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy

BACKGROUND: The clinical features of patients with small cell lung cancer (SCLC) and idiopathic pulmonary fibrosis (IPF) have not been fully elucidated. PATIENTS AND METHODS: Data on 366 patients with pathologically confirmed SCLC who had been treated with chemotherapy or chemoradiotherapy were retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanaji, Nobuhiro, Shimizu, Junichi, Sakai, Kenichiro, Ueda, Yutaka, Miyawaki, Hiroshi, Watanabe, Naohiro, Uemura, Takehiro, Hida, Toyoaki, Inoue, Takuya, Watanabe, Naoki, Oohara, Yasuhiro, Dobashi, Hiroaki, Kato, Mikiya, Kadowaki, Norimitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586036/
https://www.ncbi.nlm.nih.gov/pubmed/33086985
http://dx.doi.org/10.1177/1753466620963866
_version_ 1783599915225579520
author Kanaji, Nobuhiro
Shimizu, Junichi
Sakai, Kenichiro
Ueda, Yutaka
Miyawaki, Hiroshi
Watanabe, Naohiro
Uemura, Takehiro
Hida, Toyoaki
Inoue, Takuya
Watanabe, Naoki
Oohara, Yasuhiro
Dobashi, Hiroaki
Kato, Mikiya
Kadowaki, Norimitsu
author_facet Kanaji, Nobuhiro
Shimizu, Junichi
Sakai, Kenichiro
Ueda, Yutaka
Miyawaki, Hiroshi
Watanabe, Naohiro
Uemura, Takehiro
Hida, Toyoaki
Inoue, Takuya
Watanabe, Naoki
Oohara, Yasuhiro
Dobashi, Hiroaki
Kato, Mikiya
Kadowaki, Norimitsu
author_sort Kanaji, Nobuhiro
collection PubMed
description BACKGROUND: The clinical features of patients with small cell lung cancer (SCLC) and idiopathic pulmonary fibrosis (IPF) have not been fully elucidated. PATIENTS AND METHODS: Data on 366 patients with pathologically confirmed SCLC who had been treated with chemotherapy or chemoradiotherapy were retrospectively analyzed to investigate the clinical features of SCLC with IPF. RESULTS: A total of 97 out of the 366 patients were diagnosed with interstitial lung disease (ILD), and 75 of them had IPF. For both the limited disease (LD) and extensive disease (ED) stages, the median progression-free survival (PFS) and overall survival (OS) were significantly shorter in the patients with IPF compared with non-ILD patients. A multivariate analysis showed that poor performance status, ED stage, and the presence of IPF were associated with shorter OS. The response rate to first-line therapy was significantly lower in patients with IPF compared with the non-ILD patients. The rate of patients receiving fewer than three cycles of first-line chemotherapy was higher in patients with IPF, which was a factor of poor survival. In LD-stage patients with IPF, chemoradiotherapy was associated with longer PFS and OS compared with chemotherapy only. CONCLUSION: In patients with SCLC, the presence of IPF was associated with a lower response rate as well as shorter PFS and shorter OS. There are some cases that are suitable for chemoradiotherapy, even among patients with IPF. The reviews of this paper are available via the supplemental material section.
format Online
Article
Text
id pubmed-7586036
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-75860362020-11-03 Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy Kanaji, Nobuhiro Shimizu, Junichi Sakai, Kenichiro Ueda, Yutaka Miyawaki, Hiroshi Watanabe, Naohiro Uemura, Takehiro Hida, Toyoaki Inoue, Takuya Watanabe, Naoki Oohara, Yasuhiro Dobashi, Hiroaki Kato, Mikiya Kadowaki, Norimitsu Ther Adv Respir Dis Original Research BACKGROUND: The clinical features of patients with small cell lung cancer (SCLC) and idiopathic pulmonary fibrosis (IPF) have not been fully elucidated. PATIENTS AND METHODS: Data on 366 patients with pathologically confirmed SCLC who had been treated with chemotherapy or chemoradiotherapy were retrospectively analyzed to investigate the clinical features of SCLC with IPF. RESULTS: A total of 97 out of the 366 patients were diagnosed with interstitial lung disease (ILD), and 75 of them had IPF. For both the limited disease (LD) and extensive disease (ED) stages, the median progression-free survival (PFS) and overall survival (OS) were significantly shorter in the patients with IPF compared with non-ILD patients. A multivariate analysis showed that poor performance status, ED stage, and the presence of IPF were associated with shorter OS. The response rate to first-line therapy was significantly lower in patients with IPF compared with the non-ILD patients. The rate of patients receiving fewer than three cycles of first-line chemotherapy was higher in patients with IPF, which was a factor of poor survival. In LD-stage patients with IPF, chemoradiotherapy was associated with longer PFS and OS compared with chemotherapy only. CONCLUSION: In patients with SCLC, the presence of IPF was associated with a lower response rate as well as shorter PFS and shorter OS. There are some cases that are suitable for chemoradiotherapy, even among patients with IPF. The reviews of this paper are available via the supplemental material section. SAGE Publications 2020-10-21 /pmc/articles/PMC7586036/ /pubmed/33086985 http://dx.doi.org/10.1177/1753466620963866 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Kanaji, Nobuhiro
Shimizu, Junichi
Sakai, Kenichiro
Ueda, Yutaka
Miyawaki, Hiroshi
Watanabe, Naohiro
Uemura, Takehiro
Hida, Toyoaki
Inoue, Takuya
Watanabe, Naoki
Oohara, Yasuhiro
Dobashi, Hiroaki
Kato, Mikiya
Kadowaki, Norimitsu
Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy
title Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy
title_full Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy
title_fullStr Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy
title_full_unstemmed Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy
title_short Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy
title_sort clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586036/
https://www.ncbi.nlm.nih.gov/pubmed/33086985
http://dx.doi.org/10.1177/1753466620963866
work_keys_str_mv AT kanajinobuhiro clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT shimizujunichi clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT sakaikenichiro clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT uedayutaka clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT miyawakihiroshi clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT watanabenaohiro clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT uemuratakehiro clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT hidatoyoaki clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT inouetakuya clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT watanabenaoki clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT ooharayasuhiro clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT dobashihiroaki clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT katomikiya clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy
AT kadowakinorimitsu clinicalfeaturesofpatientswithsmallcelllungcancerandidiopathicpulmonaryfibrosistreatedwithchemotherapyorchemoradiotherapy